Abigail Yu
YOU?
Author Swipe
View article: Single-anchored Multi-modal Dense Video Captioning for Esports Broadcasts Commentaries
Single-anchored Multi-modal Dense Video Captioning for Esports Broadcasts Commentaries Open
View article: Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations
Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations Open
The development of site-specific dual-payload antibody-drug conjugates (ADCs) represents a potential advancement in targeted cancer therapy, enabling the simultaneous delivery of two distinct drugs into the same cancer cells to overcome pa…
View article: N plasma treatment on MoS<sub>2</sub>-Ti<sub>3</sub>C<sub>2</sub> composites for improved performance in sodium ion battery
N plasma treatment on MoS<sub>2</sub>-Ti<sub>3</sub>C<sub>2</sub> composites for improved performance in sodium ion battery Open
View article: Production of antibodies and antibody fragments containing non-natural amino acids in <i>Escherichia coli</i>
Production of antibodies and antibody fragments containing non-natural amino acids in <i>Escherichia coli</i> Open
Therapeutic bioconjugates are emerging as an essential tool to combat human disease. Site-specific conjugation technologies are widely recognized as the optimal approach for producing homogeneous drug products. Non-natural amino acid (nnAA…
View article: An Integrated In Vivo/In Vitro Protein Production Platform for Site-Specific Antibody Drug Conjugates
An Integrated In Vivo/In Vitro Protein Production Platform for Site-Specific Antibody Drug Conjugates Open
The XpressCF+® cell-free protein synthesis system is a robust platform for the production of non-natural amino acids containing antibodies, which enable the site-specific conjugation of homogeneous antibody drug conjugates (ADCs) via click…
View article: Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001
Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001 Open
Overexpression of CD74, a type II transmembrane glycoprotein involved in MHC class II antigen presentation, has been reported in many B-cell non-Hodgkin lymphomas (NHLs) and in multiple myeloma (MM). STRO-001 is a site-specific, predominan…
View article: 1359 Half-life extended engineered IL18 variants that escape the negative regulation of IL18BP
1359 Half-life extended engineered IL18 variants that escape the negative regulation of IL18BP Open
Background Interleukin-18 (IL18) is a proinflammatory cytokine secreted by monocytes and macrophages to promote T and NK cells activation. While wild type IL18 was shown to be efficacious in inhibiting tumor growth in animal models, limite…
View article: Inhibition of HIF-1α by Atorvastatin During 131I-RTX Therapy in Burkitt’s Lymphoma Model
Inhibition of HIF-1α by Atorvastatin During 131I-RTX Therapy in Burkitt’s Lymphoma Model Open
Backgrounds: Radioimmunotherapy (RIT) serves as a targeted therapy for non-Hodgkin lymphomas (NHL). Although HIF(Hypoxia-inducible factors)-1α is an important biomarker during radiation therapy, its role in NHL is unclear. Atorvastatin (AT…
View article: Measurement of Tumor Pressure and Strategies of Imaging Tumor Pressure for Radioimmunotherapy
Measurement of Tumor Pressure and Strategies of Imaging Tumor Pressure for Radioimmunotherapy Open
View article: Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001
Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001 Open
STRO-001 is a site-specific, predominantly single-species, fully human, aglycosylated anti-CD74 antibody-drug conjugate incorporating a non-cleavable linker-maytansinoid warhead with a drug-antibody ratio of 2 which was produced by a novel…
View article: High frequency of CD74 expression in lymphomas: implications for targeted therapy using a novel anti‐CD74‐drug conjugate
High frequency of CD74 expression in lymphomas: implications for targeted therapy using a novel anti‐CD74‐drug conjugate Open
CD74 is a type II transmembrane glycoprotein that functions as an MHC class II chaperone and displays diverse roles in immune responses. Recently, anti‐CD74 immunotherapy has shown promise as an effective treatment strategy for lymphoid ne…
View article: Neuroprotective effects of bee venom phospholipase A2 in the 3xTg AD mouse model of Alzheimer’s disease
Neuroprotective effects of bee venom phospholipase A2 in the 3xTg AD mouse model of Alzheimer’s disease Open
View article: PET Evidence of the Effect of Donepezil on Cognitive Performance in an Animal Model of Chemobrain
PET Evidence of the Effect of Donepezil on Cognitive Performance in an Animal Model of Chemobrain Open
A considerable number of patients with breast cancer complain of cognitive impairment after chemotherapy. In this study, we showed that donepezil enhanced memory function and increased brain glucose metabolism in a rat model of cognitive i…
View article: Comparison of Imaging Characteristics of<sup>124</sup>I PET for Determination of Optimal Energy Window on the Siemens Inveon PET
Comparison of Imaging Characteristics of<sup>124</sup>I PET for Determination of Optimal Energy Window on the Siemens Inveon PET Open
Purpose. 124 I has a half-life of 4.2 days, which makes it suitable for imaging over several days over its uptake and washout phases. However, it has a low positron branching ratio (23%), because of prompt gamma coincidence due to high-ene…
View article: Comparative Study of Imaging Characteristics of I-125 Imaging Using the Siemens Inveon Scanner and Siemens Symbia TruePoint
Comparative Study of Imaging Characteristics of I-125 Imaging Using the Siemens Inveon Scanner and Siemens Symbia TruePoint Open
Objective: Although Iodine-125 (125I) has been widely used for in vitro studies because of its relatively long half-life (60.1 days), 125I imaging is limited because of its low energy (27 - 35 keV), even in an animal-dedicated system. In t…